FINWIRES · TerminalLIVE
FINWIRES

$KNSA

9 stories mentioning KNSAUpdated 10d ago

Every FINWIRES story that references KNSA, newest first.

Wire

Top Midday Gainers

Kiniksa Pharmaceuticals International (KNSA) reported Tuesday a Q2 net income and sales above market expectations.Separately, Wedbush said in a report the firm is benefiting from continued momentum for Arcalyst, its treatment for recurrent pericarditis, a condition in which the sac around the heart becomes inflamed in repeated episodes.Shares surged 23% as intraday trading volume grew to over 1.9 million from a daily average of about 734,000.IQVIA (IQV) reported a year-over-year increase in Q2 adjusted earnings and revenue, and raised its 2026 outlook.Shares jumped 12%, with intraday trading volume rising to more than 3.3 million from a daily average of about 1.6 million.Incyte (INCY) on Tuesday reported Q2 non-GAAP earnings and sales above market expectations, and raised net sales guidance for 2026.Shares climbed up 8% amid a surge in intraday trading volume to over 3.3 million from a daily average of about 1.7 million.Price: $78.52, Change: $+14.98, Percent Change: +23.58%

$INCY$IQV$KNSA
Wire

Kiniksa's Arcalyst Growth Outlook Strengthens, Wedbush Says

Kiniksa Pharmaceuticals International (KNSA) is benefiting from continued momentum for Arcalyst, its treatment for recurrent pericarditis, a condition in which the sac around the heart becomes inflamed in repeated episodes, Wedbush Securities said Tuesday in a report.Arcalyst's growth continues to be driven by broadening prescriber adoption, with more than 5,000 clinicians having used the therapy since launch and returning users accounting for over half of new scripts, Wedbush said.Kiniksa shares face additional upside as Arcalyst's cash generation supports development of the company's pipeline and as newer recurrent pericarditis assets create a path for long-term expansion, the report said.Wedbush highlighted KPL-387, Kiniksa's next-generation treatment candidate, as a "de-risked" opportunity that may strengthen the company's position in IL-1 blockade for recurrent pericarditis while improving the franchise's long-term economicsWedbush increased its price target on Kiniksa's stock to $99 from $72 and maintained its outperform rating.Price: $79.38, Change: $+15.84, Percent Change: +24.93%

$KNSA
Wire

Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $99 From $72, Maintains Outperform Rating

Kiniksa Pharmaceuticals International (KNSA) has an average rating of buy and mean price target of $70, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $78.82, Change: $+15.29, Percent Change: +24.06%

$KNSA
Insider Trading

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $3,137,823, According to a Recent SEC Filing

John F. Paolini, Chief Medical Officer, on May 01, 2026, sold 58,424 shares in Kiniksa Pharmaceuticals International (KNSA) for $3,137,823. Following the Form 4 filing with the SEC, Paolini has control over a total of 65,623 Class A ordinary shares of the company, with 65,623 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1730430/000174153326000008/xslF345X05/form4-05052026_080527.xml

$KNSA
Insider Trading

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,623,481, According to a Recent SEC Filing

Sanj K Patel, Director, Chairman & CEO, on May 01, 2026, sold 48,565 shares in Kiniksa Pharmaceuticals International (KNSA) for $2,623,481. Following the Form 4 filing with the SEC, Patel has control over a total of 237,763 Class A ordinary shares of the company, with 237,763 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1730430/000153221826000008/xslF345X05/form4-05012026_080517.xml

$KNSA
Insider Trading

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $26,415,228, According to a Recent SEC Filing

Sanj K Patel, Director, Chairman and Chief Executive Officer,, on April 28, 2026, sold 508,339 shares in Kiniksa Pharmaceuticals International (KNSA) for $26,415,228. Following the Form 4 filing with the SEC, Patel has control over a total of 237,763 Class A ordinary shares of the company, with 237,763 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1730430/000153221826000006/xslF345X05/form4-04302026_100400.xml

$KNSA
Insider Trading

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $656,260, According to a Recent SEC Filing

Barry D Quart, Director, on April 28, 2026, sold 13,099 shares in Kiniksa Pharmaceuticals International (KNSA) for $656,260. Following the Form 4 filing with the SEC, Quart has control over a total of 12,546 Class A ordinary shares of the company, with 12,546 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1730430/000138424326000010/xslF345X05/form4-04292026_080403.xml

$KNSA
Wire

Wedbush Lifts Price Target on Kiniksa Pharmaceuticals International to $59 From $58, Maintains Outperform Rating

Kiniksa Pharmaceuticals International (KNSA) has an average rating of buy and mean price target of $58, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $52.19, Change: $+8.58, Percent Change: +19.67%

$KNSA
Wire

Update: Kiniksa Pharmaceuticals Q1 Earnings, Revenue Rise; 2026 Arcalyst Revenue Outlook Raised

(Updates with 2026 Arcalyst net product revenue guidance in fifth paragraph and latest stock move in the last paragraph.)Kiniksa Pharmaceuticals (KNSA) reported Q1 earnings Tuesday of $0.27 per share, up from $0.11 a year earlier.Analysts surveyed by FactSet expected $0.20.Revenue for the quarter ended March 31 was $214.3 million, up from $137.8 million a year earlier.Analysts polled by FactSet expected $206.1 million.The company raised its 2026 Arcalyst net product revenue guidance to a range of $930 million to $945 million, compared with its prior range of $900 million to $920 million. Four analysts polled by FactSet expected $913.3 million.Shares of the company were up over 16% in Tuesday trading.Price: $50.86, Change: $+7.25, Percent Change: +16.62%

$KNSA

Track with the FINWIRES app suite

FolioX
FolioX
Track KNSA in your portfolio
WheelAI
WheelAI
Analyze KNSA options with the wheel strategy
StockInsider
StockInsider
See market sentiment on KNSA